We upgrade our rating from OUTPERFORM to BUY as we raise our TP by 32% due to (1) our more upbeat view on the phosphorus business, (2) increasing our target EV/EBITDA from 6x to 7x to reflect a 50-bp reduction in our house cost of equity, and (3) a rollover of our TP to mid-2022.